New York, Dec. 19 – Citigroup Global Markets Holdings Inc. priced $20 million of contingent income autocallable securities due Dec. 20, 2024 linked to the SPDR S&P Biotech ETF, according to a 424B2 filing with the Securities and Exchange Commission.
Investors will receive a coupon of 13.5%, paid monthly, if the underlying fund closes at or above its 80% downside threshold on the related monthly observation date, plus any previously unpaid coupons.
The securities will be called automatically starting Jan. 16, 2024 at par if the price of the underlying stock is greater than or equal to its initial price and on any subsequent monthly review date.
At maturity the payout will be par unless the ETF declines by more than its 20% buffer in which case investors will lose 125% of the decline beyond the buffer.
The notes are guaranteed by Citigroup Inc.
Citigroup Global Markets Inc. is the agent.
Issuer: | Citigroup Global Markets Holdings Inc.
|
Guarantor: | Citigroup Inc.
|
Issue: | Contingent income autocallable securities
|
Underlying ETF: | SPDR S&P Biotech ETF
|
Amount: | $20 million
|
Maturity: | Dec. 20, 2024
|
Coupon: | 13.5%, paid monthly, if the underlying fund closes at or above its 80% downside threshold on the related monthly observation date, plus any previously unpaid coupons
|
Price: | Par
|
Payout at maturity: | Par unless the ETF declines by more than its buffer in which case investors will lose 125% of the decline beyond the buffer
|
Call: | Automatically starting Jan. 16, 2024 at par if the price of the underlying stock is greater than or equal to its initial price and on any subsequent monthly review date
|
Initial level: | $83.95
|
Buffer: | 20%
|
Downside leverage: | 125%
|
Pricing date: | Dec. 14
|
Settlement date: | Dec. 19
|
Agent: | Citigroup Global Markets Inc.
|
Fees: | 0.1% including a structuring fee of 0.05%
|
Cusip: | 17291TSJ8
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.